What question did this study set out to answer?

This review aims to evaluate bladder-preserving platforms for managing BCG-unresponsive non-muscle-invasive bladder cancer.

June 17, 2026OncoTargets and TherapyOpen Access

Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

View Full Paper

Ask AI

Bookmark

Authors

Review examines bladder-preserving strategies for bladder cancer, highlighting the need for treatment selection and integration.

This review aims to evaluate bladder-preserving platforms for managing BCG-unresponsive non-muscle-invasive bladder cancer.
Examined contemporary bladder-preserving strategies, including biologic platforms and device-assisted drug-delivery systems.
Discussed systemic immunotherapy and intravesical chemotherapy alternatives.
Analyzed existing literature reporting on efficacy and limitations of various approaches.
Current evidence supports bladder-preserving options but lacks definitive treatment hierarchy.
Clinically meaningful activities were reported, although data are constrained by study designs and variable follow-up.
Treatment selection involves evaluating differences in treatment burden, toxicity, and biomarker eligibility.

Zhang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark